
|Articles|December 18, 2014
- Breast Cancer (Issue 1)
- Volume 1
- Issue 1
Immune Checkpoint Inhibition in Breast Cancer
Author(s)Edith A. Perez, MD
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
Advertisement
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.
<<<
Articles in this issue
about 11 years ago
Breast Ultrasound Added to Mammography Increases Cancer Detectionabout 11 years ago
Biomarker-Driven Trial of Novel Topo-1 Inhibitor Debutedabout 11 years ago
Anti-Androgen Not for Male Cancers Aloneabout 11 years ago
Trials Seek Optimal nab-Paclitaxel Regimen for First-Line Use in TNMBCabout 11 years ago
Obesity as a Risk Factor for Inflammatory Breast Cancerabout 11 years ago
Advances in the Treatment of HER2-Positive Breast CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5










































